CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020, at 10:30 a.m. PT (1:30 p.m. ET) in San Francisco, CA.
A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Source: Editas Medicine, Inc.